General Information of Drug Combination (ID: DCFTVPW)

Drug Combination Name
Ginsenoside Rb1 Diazoxide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Ginsenoside Rb1   DMF70AB Diazoxide   DML1538
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 3.23
Bliss Independence Score: 3.23
Loewe Additivity Score: 3.79
LHighest Single Agent (HSA) Score: 3.8

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Ginsenoside Rb1 Interacts with 23 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-glucosidase (bglA) DEUO7V8 A0A509DD13_9STRE Metabolism [4]
Beta-glucosidase (bglA) DE4LKZ9 A0A3D1ZWL4_9BIFI Metabolism [4]
Beta-glucosidase (bglA) DEM6GYO A0A351PC96_9FIRM Metabolism [5], [4]
Beta-glucosidase (bglA) DE9N4OU C6WCL5_ACTMD Metabolism [6]
Beta-glucosidase (bglA) DERPJZ6 A0A4Q4LS82_BIFAN Metabolism [7]
Beta-glucosidase (bglA) DEVLXCG R7LVY8_9FUSO Metabolism [4]
Beta-glucosidase (bglA) DEUQTKA A0A249DCH3_LACRH Metabolism [7]
Beta-glucosidase (bglA) DEXRUS1 A0A267WL33_9BIFI Metabolism [8]
Beta-glucosidase (bglA) DERX7ML A0A3B8TKP6_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEOHI3U A0A0P0FEZ9_BACT4 Metabolism [8]
Beta-glucosidase (bglA) DE46IH1 A0A1T4QCU7_9PROT Metabolism [9]
Beta-glucosidase (bglA) DEE8WXK A0A076JJU4_BIFAD Metabolism [8]
Beta-glucosidase (bglA) DECBSVP A0A126SWK8_9BIFI Metabolism [8]
Beta-glucosidase (bglA) DEAVLU4 BGLFU_BIFBR Metabolism [8]
Beta-glucosidase (bglA) DEPBQES BGLS_BUTFI Metabolism [8]
Beta-glucosidase (bglA) DEGVUWH A0A174JG46_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEE8RS0 A0A174GPV4_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEC0M8H A0A174ZK85_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DE2OMS0 A0A173UNF6_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEPUNVR A0A395V8H8_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEX7SAW A0A3R6A2W5_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEE3I1P A0A412BAD0_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEASJG5 A5ZMW4_9FIRM Metabolism [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DME(s)
Ginsenoside Rb1 Interacts with 7 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Increases Expression [10]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [11]
Potassium voltage-gated channel subfamily E member 1 (KCNE1) OTZNQUW9 KCNE1_HUMAN Increases Expression [12]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Increases Phosphorylation [11]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Affects Activity [13]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [14]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DOT(s)
Indication(s) of Diazoxide
Disease Entry ICD 11 Status REF
Congenital hyperinsulinism 5A4Y Approved [2]
Hyperinsulinemia 5A4Y Approved [2]
Hypertension BA00-BA04 Approved [3]
Hypertensive emergency BA03 Approved [2]
Insulinoma 2C10.1 Approved [2]
Malignant essential hypertension BA00 Approved [2]
Diazoxide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Potassium channel unspecific (KC) TT1VOHK NOUNIPROTAC Modulator [16]
------------------------------------------------------------------------------------
Diazoxide Interacts with 8 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Secretion [17]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Secretion [17]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases Activity [18]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Secretion [17]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [19]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [19]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Increases Expression [18]
ATP-sensitive inward rectifier potassium channel 11 (KCNJ11) OTPUUELV KCJ11_HUMAN Decreases Expression [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Diazoxide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2409).
4 Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
5 Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol. 1998 Oct;50(10):1155-60.
6 Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
7 Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
8 Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
9 Genus Enhydrobacter Staley et al. 1987 should be recognized as a member of the family Rhodospirillaceae within the class Alphaproteobacteria. Microbiol Immunol. 2012 Jan;56(1):21-6.
10 Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol Pharm Bull. 2005 Oct;28(10):1903-8. doi: 10.1248/bpb.28.1903.
11 Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. Toxicol Appl Pharmacol. 2010 Jan 1;242(1):18-28. doi: 10.1016/j.taap.2009.09.009. Epub 2009 Sep 23.
12 Ginsenosides may enhance the functionality of human embryonic stem cell-derived cardiomyocytes in vitro. Reprod Sci. 2014 Oct;21(10):1312-8. doi: 10.1177/1933719114525269. Epub 2014 Mar 10.
13 Modulating effect of ginseng saponins on heterologously expressed HERG currents in Xenopus oocytes. Acta Pharmacol Sin. 2005 May;26(5):551-8. doi: 10.1111/j.1745-7254.2005.00116.x.
14 Ginsenoside Rb1 alleviates liver injury induced by 3-chloro-1,2-propanediol by stimulating autophagic flux. J Food Sci. 2021 Dec;86(12):5503-5515. doi: 10.1111/1750-3841.15968. Epub 2021 Nov 23.
15 Pharmacodynamics of ginsenosides: antioxidant activities, activation of Nrf2, and potential synergistic effects of combinations. Chem Res Toxicol. 2012 Aug 20;25(8):1574-80. doi: 10.1021/tx2005025. Epub 2012 Aug 9.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
17 Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy. J Hypertens. 2006 May;24(5):915-22. doi: 10.1097/01.hjh.0000222762.84605.03.
18 Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFkappaB. J Biol Chem. 2004 Nov 5;279(45):46748-54. doi: 10.1074/jbc.M406217200. Epub 2004 Aug 23.
19 Diazoxide-mediated growth inhibition in human lung cancer cells via downregulation of beta-catenin-mediated cyclin D1 transcription. Lung. 2009 Jan-Feb;187(1):61-7. doi: 10.1007/s00408-008-9127-1. Epub 2008 Dec 4.
20 Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicol Appl Pharmacol. 2013 Feb 1;266(3):375-84. doi: 10.1016/j.taap.2012.11.015. Epub 2012 Nov 28.